Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022

Overview

Journal J Atheroscler Thromb

Date 2023 Jan 22

PMID 36682773

Authors

Mariko Harada-Shiba

Hidenori Arai

Hirotoshi Ohmura

Hiroaki Okazaki

Daisuke Sugiyama

Hayato Tada

Kazushige Dobashi

Kota Matsuki

Tetsuo Minamino

Shizuya Yamashita

Koutaro Yokote

Affiliations

Soon will be listed here.

Citing Articles

The current landscape of personalised preventive approaches for non-communicable diseases: A scoping review.

Farina S, Osti T, Russo L, Maio A, Scarsi N, Savoia C PLoS One. 2025; 20(1):e0317379.

PMID: 39804869 PMC: 11729939. DOI: 10.1371/journal.pone.0317379.

Targeted NGS Revealed Pathogenic Mutation in a 13-Year-Old Patient with Homozygous Familial Hypercholesterolemia: A Case Report.

Chamoieva A, Mirmanova Z, Zhalbinova M, Rakhimova S, Daniyarov A, Kairov U Int J Mol Sci. 2024; 25(22).

PMID: 39595952 PMC: 11593385. DOI: 10.3390/ijms252211882.

Prevalence of genetically diagnosed familial hypercholesterolemia in Vietnamese patients with premature acute myocardial infarction.

Minh Nguyen K, Hoang S Medicine (Baltimore). 2024; 103(39):e39939.

PMID: 39331889 PMC: 11441875. DOI: 10.1097/MD.0000000000039939.

Exploration Continues.

Ogura M J Atheroscler Thromb. 2024; 32(1):20-22.

PMID: 39322569 PMC: 11706966. DOI: 10.5551/jat.ED271.

Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review.

Formisano E, Proietti E, Perrone G, Demarco V, Galoppi P, Stefanutti C Nutrients. 2024; 16(17).

PMID: 39275243 PMC: 11397408. DOI: 10.3390/nu16172927.

References

Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T . Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments. J Atheroscler Thromb. 2021; 28(9):905-925. PMC: 8532057. DOI: 10.5551/jat.RV17055. View

Moriarty P, Parhofer K, Babirak S, Cornier M, Duell P, Hohenstein B . Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016; 37(48):3588-3595. PMC: 5233802. DOI: 10.1093/eurheartj/ehw388. View

Holmes D, Schick B, Humphries K, Frohlich J . Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005; 51(11):2067-73. DOI: 10.1373/clinchem.2005.055228. View

Andersen L, Miserez A, Ahmad Z, Andersen R . Familial defective apolipoprotein B-100: A review. J Clin Lipidol. 2016; 10(6):1297-1302. DOI: 10.1016/j.jacl.2016.09.009. View

Hu P, Dharmayat K, Stevens C, Sharabiani M, Jones R, Watts G . Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141(22):1742-1759. DOI: 10.1161/CIRCULATIONAHA.119.044795. View

Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H . Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2021; 28(7):665-678. PMC: 8265428. DOI: 10.5551/jat.RV17050. View

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

Mabuchi H, Michishita I, Sakai T, Sakai Y, Watanabe A, Wakasugi T . Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis. 1986; 61(2):135-40. DOI: 10.1016/0021-9150(86)90073-0. View

Qian L, Gao Y, Zhang Y, Chu M, Yao J, Xu D . Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep. 2017; 7(1):238. PMC: 5428249. DOI: 10.1038/s41598-017-00316-3. View

10.

Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y . Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb. 2004; 11(3):146-51. DOI: 10.5551/jat.11.146. View

11.

Clauss S, Holmes K, Hopkins P, Stein E, Cho M, Tate A . Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005; 116(3):682-8. DOI: 10.1542/peds.2004-2090. View

12.

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

13.

Cohen J, Pertsemlidis A, Kotowski I, Graham R, Garcia C, Hobbs H . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37(2):161-5. DOI: 10.1038/ng1509. View

14.

Thorogood M, Seed M, De Mott K . Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG. 2009; 116(4):478-9. DOI: 10.1111/j.1471-0528.2008.02084.x. View

15.

Nakamura T, Kobayashi H, Yanagi K, Nakagawa T, Nishida M, Kihara S . Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int J Obes Relat Metab Disord. 1997; 21(7):580-6. DOI: 10.1038/sj.ijo.0800445. View

16.

Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B . Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986; 57(16):29H-35H. DOI: 10.1016/0002-9149(86)90434-0. View

17.

Raal F, Stein E, Dufour R, Turner T, Civeira F, Burgess L . PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2014; 385(9965):331-40. DOI: 10.1016/S0140-6736(14)61399-4. View

18.

Rodenburg J, Vissers M, Wiegman A, van Trotsenburg A, van der Graaf A, de Groot E . Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007; 116(6):664-8. DOI: 10.1161/CIRCULATIONAHA.106.671016. View

19.

Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y . Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2010; 17(7):667-74. DOI: 10.5551/jat.4143. View

20.

Noguchi T, Katsuda S, Kawashiri M, Tada H, Nohara A, Inazu A . The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis. 2009; 210(1):166-72. DOI: 10.1016/j.atherosclerosis.2009.11.018. View